Background: To evaluate the change in peripheral perfusion status in patients with retinal vein occlusion (RVO) during dexamethasone treatment. Methods: Thirty-five eyes of patients with macular oedema due to either branch or central retinal vein occlusion were included. At baseline, patients were treated with an intravitreal dexamethasone implant (Ozurdex â ) and followed until month 6. Wide-field angiographies were classified as ischaemic and nonischaemic. Peripheral nonperfusion (PNP) was determined manually by calculating the percentage of nonperfusion area in relation to the total visible retina (ischaemic index). Results: Thirteen eyes showed evidence of >10 disc area of PNP at baseline and were graded as ischaemic RVO. In nonischaemic eyes, the mean area of PNP was 0.3% at baseline, 0.6% after 1 month, 0.6% after 3 months and 0.6% after 6 months, respectively (p > 0.05). In ischaemic RVO, the ischaemic index was calculated to be 18% at baseline. One month after treatment, mean area of PNP was 16% and after 3 months was 19% (p = 0.8; p = 0.6). After retreatment, total PNP area was 18% (month 6; p = 0.9). During treatment, best-corrected visual acuity (BCVA) increased and central retinal thickness (CRT) decreased from baseline to final follow-up with no differences between nonischaemic/ ischaemic RVO. A significant negative correlation between the total area of PNP and visual acuity was identified (r = À0.6; p = 0.04). Conclusion: Using 200°wide-field fluorescein angiography, the ischaemic index was shown to remain stable during dexamethasone treatment. This finding was consistent in ischaemic as well as in nonischaemic conditions.
Introduction
Hypoxia following occlusion of a branch or central retinal vein causes disturbance of retinal oxygen extraction and leads to a high release of vascular endothelial growth factor (VEGF) and local inflammatory mediators. These vasopermeability factors are known to be involved in the pathogenesis of MO. Venous damage after retinal vein occlusion (RVO) is accompanied by variable amounts of retinal nonperfusion, which was shown to be directly proportional to the degree of VEGF expression. The amount of capillary damage and the occurrence of MO are the causes related to substantial visual impairment among patients with RVO (Aiello et al. 1995; Vinores et al. 1999; Augustin et al. 2010) .
Branch and central retinal vein occlusion (BRVO and CRVO) are classified into ischaemic (nonperfused) and nonischaemic (perfused) with different consequences for functional and anatomical outcome. Ischaemic RVO was defined by the Central Retinal Vein Occlusion Study (CVOS) as an amount of capillary nonperfusion of at least 10 disc areas. The classification was developed to identify patients with high risk for neovascular complications as the extent of capillary nonperfusion strongly correlates with the occurrence of neovascular glaucoma (CVOS 1995) . Besides, the clinical course and management of patients with RVO depend on the extent of retinal nonperfusion. Severity of MO and the visual prognosis were shown to correlate with the degree of ischaemic damage (The Central Vein Occlusion Study Group 1995), and in addition, the treatment requirement was reported to increase with the size of peripheral retinal nonperfusion (PNP) (Aghdam et al. 2016) .
Anti-VEGF agents and corticosteroids are treatment options for the management of patients with MO secondary to RVO and were both shown to have significant impact on functional and morphological outcome as confirmed by the BRAVO, CRUISE and GENEVA trials (Brown et al. 2010; Campochiaro et al. 2010) . In those former studies, evaluation of capillary nonperfusion within the Early Treatment Diabetes Retinopathy Study (ETDRS) subfields showed progression of nonperfusion in untreated RVO. Antagonism of VEGF was reported to prevent progression of nonperfusion in a majority of patients, and reperfusion was supported (Campochiaro et al. 2013) . The changes in the area of nonperfusion were also evaluated during dexamethasone treatment and revealed no changes over time, again evaluated in the ETDRS subfields with limited field of view of the peripheral vascular damage (Sadda et al. 2013) . With the use of 200°wide-field imaging, areas of nonperfusion were shown in the far periphery of the retina, which cannot be visualized using the standard 30°or 50°fluores-cein angiography (FA). So, limited evidence exists about the status of PNP during intravitreal treatment as there were limited means to visualize the peripheral changes in the past. Hence, this study aimed to evaluate the extension and changes of PNP using 200°wide-field FA in a population treated with intravitreal dexamethasone.
Patients and Methods
In this prospective analysis, 35 eyes of 35 consecutive patients with MO due to either BRVO or CRVO were included for analysis (21 patients with BRVO and 14 patients with CRVO). Inclusion criteria comprised evidence of MO (>300 lm) due to BRVO/CRVO involving the fovea as confirmed by optical coherence tomography (OCT). Patients with severe macular ischaemia as seen on FA were not included.
At baseline, all patients were treated with 0.7 mg intravitreal dexamethasone implant (Ozurdex Ò , Allergan, Inc., Irvine, CA, USA) and followed monthly until month 6. Retreatment with dexamethasone implant was carried out if an increase in central retinal thickness (CRT >300 lm) combined with visual loss of ≥5 ETDRS letters was detected earliest at month 4. Distance visual acuity (VA) and morphological analysis using spectral-domain OCT were performed at baseline and monthly until month 6. 200°wide-field FA was performed at baseline, month 1, month 3 and month 6.
Patients signed an informed consent form prior to inclusion in the study, which was approved by the ethics committee of the Medical University of Vienna. The study design adheres to the tenets of the Declaration of Helsinki. The trial was registered at the European Clinical Trials Register (EudraCT 2012-000800-13).
Study variables
Best-corrected visual acuity (BCVA) was assessed for both eyes. Spectraldomain OCT (Spectralis SD-OCT, Heidelberg Engineering, Heidelberg, Germany) images were obtained monthly to evaluate the morphological retinal changes. 200°wide-field FA, using the Optos imaging system (Optos Ò , Southborough, MA, USA), was performed using standard sequence times at baseline, month 1, month 3 and month 6 to identify the extent of capillary nonperfusion. Fluorescein angiography images were quantified manually for the total area of PNP by calculating the percentage of the total visible retina (ischaemic index) using ImageJ Ò Version 1.8 (Image Processing and Analysis in Java, National Institute of Health, MD, USA; available at http://imagej.nih. gov/ij). The ischaemic index was calculated according to previously described methodology (Tan et al. 2016) . Images were selected during the arteriovenous phase of the angiogram (between 45 seconds and 2 min) and graded manually for peripheral PNP. The total region of the visible retina was encircled using elliptical or brush selection at baseline. The total area was then calculated automatically in pixel. The border of the encircled total visible area from the baseline image was restored for all follow-up images to ensure calculation of the same area at all time-points. The optic disc was used as a reference to identify correct image rotation, and rotation was performed until the optic disc with the selected vessels matched the baseline image. Using the measurement function, the area of PNP was delineated and divided by the total image area to measure the percentage of the nonperfused retinal area (Fig. 1) .
Statistical analyses were performed using descriptive statistics for all variables and data frequency. The aim of these analyses was to describe the changes of PNP during dexamethasone treatment. Baseline variables were analysed for all patients with perfused or nonperfused RVO. Differences between groups and changes over time were calculated using unpaired and Fig. 1 . Representative images of a patient with branch retinal vein occlusion (BRVO) at baseline, month 3 and month 6 (from left to right). The ischaemic index was calculated to be 8.3% at baseline, 8.2% at month 3 and 7.8% at month 6. The white line marks the area of peripheral nonperfusion as imaged using wide-field fluorescein angiography. paired two-sided t-tests. The level of significance was set to 0.05.
Results
Within this prospective analysis, we included a total of 35 patients (23 men and 12 women) with MO due to BRVO (n = 21) and CRVO (n = 14). At baseline, 13 patients were graded according to the definition of the CVOS (4) as ischaemic RVO (62% BRVO and 38% CRVO). Twenty-two eyes were nonischaemic (59% BRVO and 41% CRVO).
The mean age of RVO patients was 68.4 AE 11 years (68.6 AE 12 nonischaemic and 68.3 AE 8 ischaemic RVO). The BCVA of the patients ranged from 20/400 to 20/25 with a mean of 63.8 AE 14 letters at baseline (65 AE 15 letters nonischaemic/ 62.0 AE 12 letters ischaemic RVO; p = 0.6). Mean CRT at baseline was 553 AE 149 lm (590 AE 168 lm nonischaemic/531 AE 132 lm ischaemic RVO; p = 0.3). The mean area of PNP (ischaemic index) was 18 AE 12% (range 8.3-52.7%) in the ischaemic RVO group at the time of first treatment. In patients with nonischaemic RVO, mean PNP area was 0.3 AE 1% (range 0-2.6%).
Twenty-two eyes received retreatment at month 4, eight at month 5 and five at month 6 due to recurrence of MO. Comparing nonischaemic and ischaemic RVO, 13/9 (69%/59%) eyes received retreatment at month 4, 5/3 (23%/23%) at month 5 and 4/1 (8%/ 18%) at month 6 due to recurrence of MO (p > 0.05).
In nonischaemic RVO, the mean area of PNP was calculated to be 0.3 AE 1% at baseline. One month after initial dexamethasone treatment, mean PNP area was 0.6 AE 1% and 3 months after treatment was 0.6 AE 2% (p = 0.5; p = 0.9). After retreatment, the mean PNP area was 0.6 AE 1% (month 6; p = 0.7 in comparison with baseline). No patient showed an increase or decrease of 10% or more of PNP at month 6 in comparison with baseline. In eyes graded as ischaemic RVO, mean area of PNP was 18 AE 12% at baseline. One month after initial dexamethasone treatment, mean PNP area was 16 AE 13% and 3 months after treatment was 19 AE 13% (p = 0.8; p = 0.6). After retreatment, the mean PNP area was 18 AE 16% (month 6; p = 0.9 in comparison with baseline). In two of the 13 patients with ischaemic RVO, an increase in 10% or more of PNP was observed, while in one patient a decrease in 10% or more of PNP was seen at month 6 in comparison with baseline. No patient developed macula ischaemia during the course of the study. In Fig. 2 , the relative frequency of cases separated in <10% and >10% PNP area at baseline, month 1, month 3 and month 6 is presented.
Baseline VA was 64 AE 14 mean seen letters (65 AE 15 letters in nonischaemic RVO/62 AE 12 letters in ischaemic RVO p = 0.6). VA improved to 73 AE 14 letters (76 AE 13 letters in nonischaemic RVO/70 AE 14 letters in ischaemic RVO; p = 0.2) after initial dexamethasone treatment (p < 0.001) and to 68 AE 14 (69 AE 13 letters in nonischaemic RVO and 66 AE 14 letters in ischaemic RVO; p = 0.6) after 3 months (p = 0.06 in comparison with baseline). After retreatment, mean seen letters increased to 70 AE 17 (70 AE 18 letters in nonischaemic RVO/69 AE 15 letters in ischaemic RVO p = 0.9) (p = 0.02 in comparison with baseline).
Central retinal thickness was 553 AE 149 lm at baseline (531 AE 131 lm in nonischaemic RVO and 590 AE 168 lm in ischaemic RVO; p = 0.3). Central retinal thickness decreased to 301 AE 67 lm (312 AE 67 lm in nonischaemic RVO and 282 AE 62 lm in ischaemic RVO; p = 0.2) after initial dexamethasone treatment (p < 0.001) and to 400 AE 173 lm (410 AE 142 lm in nonischaemic RVO and 387 AE 209 lm in ischaemic RVO; p = 0.7) after 3 months (p < 0.001 in comparison with baseline). After retreatment, CRT decreased to 297 AE 88 lm (305 AE 61 lm in nonischaemic RVO and 285 AE 118 lm in ischaemic RVO; p = 0.5) (p < 0.001 in comparison with baseline).
A negative correlation was identified between VA and amount of PNP (r = À0.6; p = 0.04). No correlation existed between CRT and amount of PNP (r = 0.4; p = 0.3).
Discussion
The present study included patients with BRVO and CRVO undergoing dexamethasone treatment and showed peripheral capillary nonperfusion to be stable as evaluated using wide-field FA. To our knowledge, this is the first study prospectively evaluating the extent of PNP during dexamethasone treatment using 200°wide-field methodology. As ischaemia is associated with the expression of angiogenic and inflammatory mediators, the visualization of the area of PNP and the knowledge about the changes during treatment are important to evaluate the treatment response and risk for complications. To date, limited evidence exists about the role of peripheral vascular occlusion in the course of RVO. As the visualization of the far retinal periphery was limited in the past, only a few data exist about the change in peripheral retinal ischaemia during intravitreal treatment. Previous studies investigated the extent and the presence of retinal nonperfusion in RVO mainly by creating a 7-field montage of multiple fields or by grading capillary nonperfusion within the ETDRS subfields not visualizing the periphery of the retina (The Central Vein Occlusion Study Group 1995). With the introduction of widefield angiography, visualization of the far periphery was enabled and showed large areas of PNP in some patients, which was missed using standard imaging with a 30-50°field of view (Spaide 2011; Wykoff et al. 2015) . Studies proposed that these nonperfused areas are the source of various pathogenic pathways including angiogenic VEGF and inflammatory cytokine expression. Higher concentrations of angiogenic and inflammatory cytokines were reported in ischaemic compared to nonischaemic RVO (Pe'er et al. 1998; Jung et al. 2014) .
Retinal vein occlusion is characterized by variable amounts of capillary nonperfusion, and the severity of ischaemia was shown to be linked to the severity of disease and the amount of VEGF levels. In experimental studies, hypoxia was linked to VEGF expression in patients with CRVO (Pe' et al. 1998) . VEGF was identified as the major factor involved in the pathogenesis of MO and linked to neovascular complications. PNP area was identified as the source for massive VEGF production, and it was shown that in untreated eyes, the area of PNP increased over time (Scott et al. 2009; Campochiaro et al. 2013) . A study by Prasad et al. (2010) demonstrated an association between nonperfusion and MO in a majority of patients. By anti-VEGF treatment, stabilization of capillary nonperfusion was reported using a grading protocol evaluating ETDRS subfields. In this study, they hypothesized that high levels of VEGF contribute to worsening of retinal nonperfusion and by antagonism of VEGF this could be prevented. However, in a study by Wykoff et al. (2015) , PNP was evaluated during 3 years using a wide-field lens (150°) and a loss of retinal perfusion of 8% per year despite anti-VEGF treatment was shown.
Macular oedema (MO) due to RVO is hypothesized to be associated with retinal nonperfusion. However, Prasad et al. (2010) reported some patients to have MO without any signs of nonperfusion seen on FA and MO to persist or recur despite the treatment of PNP. This leads to the assumption that beside VEGF, other factors or pathways may be involved in MO development. In intraocular fluids, proinflammatory proteins (IL-6, MCP-1 and ICAM-1) beside VEGF were shown to be significantly upregulated in patients with CRVO and to correlate with the severity of MO (Funk et al. 2009; Noma et al. 2009 ). Dexamethasone was introduced into the treatment of MO due to RVO as corticosteroids are known to have anti-inflammatory properties. The hypothesized mechanism of action is reduction in vascular permeability or modulation of the VEGF receptor (Wilson et al. 1992; Edelman et al. 2005) . It was shown that dexamethasone has a positive impact on functional and morphological outcome in patients with RVO; however, limited evidence exists about the impact on the peripheral ischaemia. One study evaluated changes during dexamethasone treatment on the capillary perfusion status. Results from this investigation showed no change in the mean area of nonperfusion (in disc diameter). The study used data obtained with standard FA and evaluated the extent of nonperfusion in the ETDRS subfields (Sadda et al. 2013 ). In our data, including the evaluation of the peripheral retina, the amount of nonperfusion was also shown to remain stable during treatment with intravitreal dexamethasone. It seems reasonable that there exists a synergistic effect of a combined therapy with anti-VEGF and corticosteroids for patients with RVO targeting both inflammatory and angiogenic pathways. A study evaluating a combined treatment with bevacizumab and dexamethasone reported an additional positive effect regarding a reduction in retreatment requirement (Singer et al. 2012) . Combined approaches should be evaluated in future studies regarding their influence on the peripheral ischaemic changes.
We reported a negative correlation between VA and the changes of PNP indicating that a close monitoring and the treatment of those patients with high amount of ischaemic changes are required to preserve visual function. According to that, Spaide (2011) reported the size of PNP to be negatively correlated with VA using wide-field imaging. In contrast, earlier studies grading the extent of nonperfusion in the 10 subfields of the ETDRS did not report a significant correlation between the changes in VA and changes in nonperfusion (Sadda et al. 2013 ) again pointing out the value of visualizing and evaluation of the peripheral retinal changes during disease progression.
However, using wide-field FA, imaging of the entire retina and the exact amount of nonperfusion is not possible. Creating a summarized image by merging fields of the retina through gazing into different directions was described to better determine the exact size of PNP and maximize the field of view. This study includes a limited number of patients and includes cases with a longer duration of RVO being a limitation.
Further investigations should focus on acute cases, which are potentially more responsive to treatment. Nevertheless, to conclude, this study represents the course of peripheral vascular occlusion during dexamethasone treatment and underlines the importance of wide-field imaging in patients with retinal vascular disease and peripheral vascular changes, with similar functional and anatomical outcome for nonischaemic and ischaemic RVO. However, VA correlated with the extension of PNP and future investigations should focus on peripheral vascular changes, as they seem to be important for the management of patients with RVO.
